Skip to content

Heron Therapeutics’ HTX-011 shows positive action in hernia repair surgery

September 16, 2020

Heron Therapeutics (NASDAQ:HRTX) announces results from EPOCH 2 follow-on study evaluating the efficacy and safety of locally administered HTX-011 300 mg bupivacaine / 9 mg meloxicam into the surgical site in combination with a postoperative non-opioid multimodal analgesia regimen of over-the-counter oral acetaminophen and ibuprofen in 63 patients undergoing open inguinal hernia repair surgery.

In in this study, more than 90% of patients did not require opioids to manage their postoperative pain during the first 72 hours.

87% of patients were opioid-free through Day 10 and 83% throughout the entire 28-day follow-up period of the study.

Mean pain intensity scores were similar between cohorts and never rose above the mild pain range (NRS <4) throughout the 72-hour postoperative period.

Addition of an intraoperative dose of ketorolac did not provide additional benefit for pain intensity or opioid use.

HTX-011 was well tolerated, with a safety profile comparable to placebo and bupivacaine solution.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: